psoriasis

decision path change of plans arrows business decision
Biotech

Lilly changes lead psoriasis program from $2.4B Dice buyout

Lilly kicked DC-806 to the curb as part of a third-quarter cull that also affected the PD-1 autoimmune prospect peresolimab.
Nick Paul Taylor Oct 30, 2024 10:00am
blocks stack target climb build arrow meet

Awaiting regulator verdict, Innovent posts latest psoriasis win

Oct 29, 2024 9:50am
target reach ladder climb meet win beat competition

InnoCare's TYK2 inhibitor holds its own in ph. 2 psoriasis trial

Oct 9, 2024 9:10am
stock market down crash fail shares

Ventyx's last hope for inflammatory med ends in Crohn's failure

Jul 29, 2024 9:45am
Wall Street IPO initial public offering markets shares stock

Alumis downsizes IPO, tacks on private placement

Jun 28, 2024 5:02am
Photo of Wall Street street sign with american flags in the background

Alumis eyes $300M IPO to fund clinical-stage TYK2 pipeline

Jun 24, 2024 8:14am